Category: Legislative

Legislative

Legislative

Threat to Ad Tax Deduction Is “Immediate,” Davidson Tells Coalition Rising Leaders

Threat to Ad Tax Deduction Is “Immediate,” Davidson Tells Coalition Rising Leaders

June 11, 2019 – Although pharmaceutical advertisers have been able to stop legislation to eliminate or reduce the deductibility of drug advertising as a business expense in the past, the times, politics and a pressing need for revenue have changed the equation, according to Jim Davidson, chair of The Advertising Coalition. “It is very much […]

Read more

DTC Advertising

Movement Afoot on Eliminating Ad Tax Deduction, Requiring List Prices in DTC Drug Ads

Movement Afoot on Eliminating Ad Tax Deduction, Requiring List Prices in DTC Drug Ads

March 25, 2019 – Several moves that could change the way prescription drug marketing and communications are conducted are being made in Washington, with the House Ways and Means Committee about to begin markup on a tax measure that could include eliminating the deductibility of drug marketing costs, and the Office of Management and Budget […]

Read more

Legislative

New Bill Announced to End Marketing Tax Deduction

New Bill Announced to End Marketing Tax Deduction

Jan. 16, 2019 – Sens. Jeanne Shaheen (D-N.H.) and Elizabeth Warren (D-Mass.) have co-authored a bill that would “deny the deduction for advertising and promotional expenses for prescription drugs.” The bill, announced Jan. 11, is titled the “End Taxpayer Subsidies for Drug Ads Act.” “This bill raises significant First Amendment questions,” pointed out Jon Bigelow, […]

Read more

Legislative

Position on Reporting Reprints and Textbooks Appears to Be Shifting

Position on Reporting Reprints and Textbooks Appears to Be Shifting

Sept. 27, 2018 – Although it was the Obama administration’s position that reprints and textbooks received by physicians were transfers of value that were fully reportable under the Sunshine Act Open Payments regulation, the Trump administration and Congress are taking another look at the matter, according to John Kamp, Washington Counsel, Coalition for Healthcare Communication. […]

Read more

Legislative

New Jersey “Gift Ban” Up for Revision

New Jersey “Gift Ban” Up for Revision

July 27, 2018 – The aggressive “gift ban” enacted by New Jersey regulators on Jan. 15 is subject to revisions under the administration of New Jersey Governor Phil Murphy, according to an article posted yesterday in Policy & Medicine, which states that a proposed rule enumerating the changes will be published on Aug. 6. Policy […]

Read more

Legislative

House Appropriations Bill Does Not Include Authorization of Mandatory Drug Prices in Ads

House Appropriations Bill Does Not Include Authorization of Mandatory Drug Prices in Ads

July 13, 2018 – On the “no news is good news” front, the House Appropriations Committee voted this week on next year’s funding level for the U.S. Department of Health and Human Services (HHS) without taking up an amendment to give HHS and FDA explicit authority to mandate drug list prices in consumer advertising. “What […]

Read more

Legislative

Azar Says FDA Has Authority to Require List Prices in Drug Ads

Azar Says FDA Has Authority to Require List Prices in Drug Ads

June 13, 2018 – At a Senate Committee on Health, Education, Labor & Pensions hearing on drug pricing held yesterday, Department of Health and Human Services (HHS) Secretary Alex Azar told the committee that it is his belief that “we have the authority to require list price disclosure in TV ads,” as proposed in the […]

Read more

Legislative

McCaskill Strikes Again with Transparency Bill To Expand Sunshine Provisions

McCaskill Strikes Again with Transparency Bill To Expand Sunshine Provisions

June 8, 2018 – Sen. Claire McCaskill (D-Mo.), who announced a bill in March that would amend the tax code to “deny the deduction for advertising and promotional expenses for prescription drugs,” continues to look for ways to restrict prescription drug company activities, now introducing a bill that would significantly expand reporting under the Sunshine […]

Read more

Legislative

Oregon Transparency Bill Signed into Law

Oregon Transparency Bill Signed into Law

April 2, 2018 – An Oregon transparency bill introduced in February was signed into law March 13 by Oregon Gov. Kate Brown (D), requiring drug companies not only to report drug prices to the state annually, but also to report costs associated with developing and marketing their drugs. “The Oregon bill (HB 4005) is the […]

Read more

Legislative

Oregon Transparency Bill Calls for Reporting of Marketing Costs

Oregon Transparency Bill Calls for Reporting of Marketing Costs

Feb. 5, 2018 – A bill to increase price transparency in Oregon, scheduled to be introduced Feb. 5, would require prescription drug manufacturers not only to report drug prices to the state annually, but also would require them to report costs associated with developing and marketing their drugs. If passed, Oregon House Bill 4005 would […]

Read more